These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 15983956)

  • 1. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study.
    Bianchi S; Bigazzi R; Campese VM
    Am J Kidney Dis; 2005 Jul; 46(1):45-51. PubMed ID: 15983956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease.
    Bianchi S; Bigazzi R; Campese VM
    Kidney Int; 2006 Dec; 70(12):2116-23. PubMed ID: 17035949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
    Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease.
    Pisoni R; Acelajado MC; Cartmill FR; Dudenbostel T; Dell'Italia LJ; Cofield SS; Oparil S; Calhoun DA
    J Hum Hypertens; 2012 Aug; 26(8):502-6. PubMed ID: 21677673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.
    Navaneethan SD; Nigwekar SU; Sehgal AR; Strippoli GF
    Clin J Am Soc Nephrol; 2009 Mar; 4(3):542-51. PubMed ID: 19261819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mineralcorticoid receptor blockers in chronic kidney disease.
    Erraez S; López-Mesa M; Gómez-Fernández P
    Nefrologia (Engl Ed); 2021; 41(3):258-275. PubMed ID: 36166243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Bolignano D; Palmer SC; Navaneethan SD; Strippoli GF
    Cochrane Database Syst Rev; 2014 Apr; (4):CD007004. PubMed ID: 24782282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
    Khosla N; Kalaitzidis R; Bakris GL
    Am J Nephrol; 2009; 30(5):418-24. PubMed ID: 19738369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of spironolactone in combination with angiotensin-converting enzyme inhibitors or Angiotensin receptor blockers in patients with proteinuria.
    Kim HY; Bae EH; Ma SK; Kim SW
    Kidney Blood Press Res; 2014; 39(6):573-80. PubMed ID: 25531940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy.
    Van Buren PN; Adams-Huet B; Nguyen M; Molina C; Toto RD
    Clin J Am Soc Nephrol; 2014 Feb; 9(2):295-301. PubMed ID: 24408116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of spironolactone to dual blockade of renin angiotensin system dramatically reduces severe proteinuria in renal transplant patients: an uncontrolled pilot study at 6 months.
    González Monte E; Andrés A; Polanco N; Toribio MJ; Santana R; Gutiérrez Martínez E; González J; Ramírez E; Hernández A; Morales E; Praga M; Morales JM
    Transplant Proc; 2010 Oct; 42(8):2899-901. PubMed ID: 20970564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The antiproteinuric effect of the blockage of the renin-angiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective? ].
    Morales E; Huerta A; Gutiérrez E; Gutiérrez Solís E; Segura J; Praga M
    Nefrologia; 2009; 29(5):421-9. PubMed ID: 19820754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beneficial long-term effect of aldosterone antagonist added to a traditional blockade of the renin-angiotensin-aldosterone system among patients with obesity and proteinuria.
    Morales E; Gutiérrez E; Caro J; Sevillano A; Rojas-Rivera J; Praga M
    Nefrologia; 2015; 35(6):554-61. PubMed ID: 26519114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases.
    Bianchi S; Bigazzi R; Campese VM
    Am J Kidney Dis; 2010 Apr; 55(4):671-81. PubMed ID: 20097461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease.
    Edwards NC; Steeds RP; Chue CD; Stewart PM; Ferro CJ; Townend JN
    Br J Clin Pharmacol; 2012 Mar; 73(3):447-54. PubMed ID: 21950312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review.
    Bomback AS; Kshirsagar AV; Amamoo MA; Klemmer PJ
    Am J Kidney Dis; 2008 Feb; 51(2):199-211. PubMed ID: 18215698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Navaneethan SD; Nigwekar SU; Sehgal AR; Strippoli GF
    Cochrane Database Syst Rev; 2009 Jul; (3):CD007004. PubMed ID: 19588415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]).
    Am J Cardiol; 1996 Oct; 78(8):902-7. PubMed ID: 8888663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of spironolactone on urinary protein excretion in patients with chronic kidney disease.
    Sengul E; Sahin T; Sevin E; Yilmaz A
    Ren Fail; 2009; 31(10):928-32. PubMed ID: 20030528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.